Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
Dr. Dereck Mush, MD, MBA
Exscientia
Uses AI to design patient first precision medicines and optimize clinical trials.
What they do
Exscientia operates an artificial intelligence platform to design small molecule drugs and match patients with optimal treatments. The platform automates drug design and evaluates drug efficacy on actual human tissue samples to assist biopharmaceutical partners.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Public
- Headquarters
- Oxford, United Kingdom
- Region
- Europe
- Founded
- 2012
- Total funding
- $440M raised
Notable investors: SoftBank Vision Fund, Mubadala Investment Company, BlackRock, Bristol Myers Squibb.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
AI is moving upstream, from molecule design into disease target identification itself
Dr. Dereck Mush, MD, MBA